These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 1029192)

  • 1. [Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model].
    Leinweber B; Mahrt R
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():300-3. PubMed ID: 1029192
    [No Abstract]   [Full Text] [Related]  

  • 2. [Icterus caused by rifampicin and isoniazide].
    Haber I; Hubens H; Buyssens N
    Tijdschr Gastroenterol; 1974; 17(3):165-76. PubMed ID: 4454055
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experimental study of liver damage due to rifampicin and rifampicin-isoniazid combination].
    Rossolini A; Cellesi C; Debolini A
    Farmaco Prat; 1973 Jun; 28(6):345-55. PubMed ID: 4714054
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reversible acute hepatic failure after treatment with association of isoniazide-rifampicin (author's transl)].
    Le Guillou M; L'Henaff F; Boisseau M; Castaing Y; Bourdalle-Badie C
    Sem Hop; 1981 Jun 18-25; 57(25-28):1199-201. PubMed ID: 6266037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of tocopherol and anti-hypoxic agents in liver damage caused by antitubercular agents].
    Skakun NP; Slivka IuI
    Probl Tuberk; 1991; (3):57-9. PubMed ID: 1871097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Toxic hepatitis (liver and antitubercular drugs)].
    Kohan S
    Acta Gastroenterol Latinoam; 1977 Dec; 7(4):301-4. PubMed ID: 617560
    [No Abstract]   [Full Text] [Related]  

  • 7. [Determination of adverse reactions of chronic drug therapy as examplified with the hepatotoxic action of isoniazid and rifampicin].
    Bartmann K
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1518-29. PubMed ID: 347784
    [No Abstract]   [Full Text] [Related]  

  • 8. [Icterigenic hepatitis during the treatment with combined isoniazid and rifampicin. Clinical and experimental observations].
    Marche J; Hugues FC; Graisely B; Marche C
    Rev Tuberc Pneumol (Paris); 1971; 35(1):55-76. PubMed ID: 5559725
    [No Abstract]   [Full Text] [Related]  

  • 9. [Synergistic effect of rifampicin on hepatotoxicity of isoniazid].
    Skakun NP; Shman'ko VV
    Antibiot Med Biotekhnol; 1985 Mar; 30(3):185-9. PubMed ID: 4015060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present views on isoniazid and isoniazid-rifampicin hepatitis.
    Pessayre D
    Agressologie; 1982 Jan; 23(A):13-5. PubMed ID: 7081577
    [No Abstract]   [Full Text] [Related]  

  • 11. [Isoniazid-rifampicin: a model for hepatotoxicity and for bibliographic Anglomania].
    Toulet J; Viteau JM
    Gastroenterol Clin Biol; 1978; 2(8-9):756-7. PubMed ID: 361483
    [No Abstract]   [Full Text] [Related]  

  • 12. [Detection of the effects of the rifampin-isoniazid combination on the human liver].
    Plomteux G; Heusghem C; Ferdinande R; Lecoq A; Winandy A; Parmentier JC
    Nouv Presse Med; 1974 Mar; 3(12):727-32. PubMed ID: 4836506
    [No Abstract]   [Full Text] [Related]  

  • 13. [Liver damage from tuberculosis treatment].
    Keiner F
    Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
    [No Abstract]   [Full Text] [Related]  

  • 14. PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.
    Lyoumi S; Lefebvre T; Karim Z; Gouya L; Puy H
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):439-41. PubMed ID: 23916555
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug-induced hepatitis during a treatment associating isoniazid and rifampicin].
    Jean R; Bonnet H; Pages P; Dumas R; Greze J
    Ann Pediatr (Paris); 1972 Apr; 19(4):307-11. PubMed ID: 5075678
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fulminant hepatitis in patients with mixed connective tissue disease under antitubercular treatment with hydrazide and rifampicin].
    Waitzberg VR; Gayotto LC
    Rev Hosp Clin Fac Med Sao Paulo; 1982 Feb; 37(1):48-51. PubMed ID: 7123064
    [No Abstract]   [Full Text] [Related]  

  • 17. Isoniazid-rifampicin-induced submassive hepatic necrosis.
    Kasantikul V
    J Med Assoc Thai; 1989 Jan; 72(1):56-8. PubMed ID: 2723568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of acute hepatitis occurred during treatment with isoniazid and rifampicin (author's transl)].
    Kameda K; Kawabata S; Shirai S
    Kekkaku; 1980 May; 55(5):247-51. PubMed ID: 7412075
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinically apparent liver damage during brief tuberculosis therapy].
    Estay S; Armas Merino R; Vega C; Soto JR
    Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fatal liver cell necrosis following short-term administration of isoniazid and rifampicin to a patient already under treatment with antiepileptics].
    Lenders JW; Bartelink AK; van Herwaarden CL; van Haelst UJ; van Tongeren JH
    Ned Tijdschr Geneeskd; 1983 Mar; 127(10):420-3. PubMed ID: 6835412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.